Skip to Content

Gary E. Gallick, PhD

Present Title & Affiliation

Primary Appointment

Professor, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Unit Number: 0018-4
Houston, TX 77030-4009
Room Number: T7.3891

Education & Training

Degree-Granting Education

1981 University of Illinois, Urbana, IL, PHD, Microbiology
1980 University of Illinois, Urbana, IL, MS, Microbiology
1974 University of Michigan, Ann Arbor, MI, BS, Microbiology

Postgraduate Training

1981-1984 Postdoctoral Fellow, The University of Texas MD Anderson Cancer Center, Houston, TX
1975-1981 Predoctoral Fellow, University of Illinois, Urbana, IL


Academic Appointments

Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001-2008
Associate Professor, Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1998-2001
Associate Virologist and Associate Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, 1991-1998
Assistant Virologist and Assistant Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, 1986-1991
Research Associate, Department of Tumor Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1984-1986
Postdoctoral Fellow, Department of Virology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1981-1984
Research Assistant, Department of Microbiology, University of Illinois, Urbana, IL, 1975-1981
Teaching Assistant, Department of Microbiology and School of Basic Medical Sciences, University of Illinois, Urbana, IL, 1975-1979

Administrative Appointments/Responsibilities

Distinguished Teaching Professor, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012
Director of Education, Department of Genitourinary Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008

Other Appointments/Responsibilities

Member, Academic Standards Committee, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 2012-2013
Director, Program in Cancer Metastasis, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 2009
President, Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 2000-2001
Member, Program Coordinating Committee, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1999-2001
Chairman, Executive Committee, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1999-2000
Vice President, Graduate Faculty, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1999-2000
Founding Chairman, Program Coordinating Committee, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1997-1999
Member, MD/PhD Committee, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1996-1999
Chairman, Admissions Committee, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1996-1997
Member, Executive Committee, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1996-1997
Director, Graduate Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1995-2001
Director, Core Curriculum for the Graduate Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1995
Member, Admissions Committee, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1994-1996
Chairman, Academic Standards Committee, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1991-1992
Member, Executive Committee, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1991-1992
Member, Graduate Executive Committee, Cancer Biology Program, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1987-2012
Director, Molecular Virology and Gene Therapy Program, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1987-1988
Member, Molecular Virology and Gene Therapy Program, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1984
Member, Cancer Biology Program, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 1984

Endowed Positions

Andrew Sowell-Wade Huggins Professorship in Cancer Research, The University of Texas Graduate School of Biomedical Sciences, Houston, TX, 2006-2007


Consultant, Exelixis, San Francisco, CA, 3/2011-3/2012
Consultant, Scarrit Group, Inc, San Francisco, CA, 1/2011
Consultant, Bristol-Myers Squibb, Milan, Italy, 2010
Consultant, Bristol Myers Squibb, Chicago, IL, 2007-2009
Consultant, Kinex Pharmaceuticals, Buffalo, New York, 2006-2009
Consultant, The State of Florida Higher Education Coordinating Board, Florida, 2006
Consultant, AstraZeneca, London, England, 2003-2005
Consultant, The University of South Florida, Moffitt Cancer Center, Florida, 2001-present
Consultant, The State of Florida Higher Education Coordinating Board, Florida, 2001

Institutional Committee Activities

Member, The Salivary Gland UO1, Internal Advisory Board for Career Development Projects, 2010
Member, Head and Neck SPORE, Internal Advisory Committee for Career Development Awards, 2010
Member, Cell Line Authentication Committee, 2009-2010
Member, Faculty Achievement Award, Education Subcommittee, 2009
Member, MD Anderson Academy of Health Science Educators, 2008-present
Chairman, Graduate Education Committee, 2007-2009
Chairman, Office of Academic Affairs Odyssey Committee for Postdoctoral Fellows, 2007
Chairman, Gynecology/Oncology Faculty Search Committee, 2007
Chairman, Promotion and Tenure Committee, 2006-2007
Co-Chairman, Office of Academic Affairs Odyssey Committee for Postdoctoral Fellows, 2006
Member, PRS Faculty Development Leave Policy Subcommittee, 2005
Member, Office of Academic Affairs Odyssey Committee for Postdoctoral Fellows, 2005
Member, Steering Committee of the Alumni and Faculty Association, 2004-2010
Member, Trainee and Alumni Affairs, 2004-2009
Member, Multidisciplinary Research Advisory Committee, 2004-2007
Member, Faculty Compensation Committee, 2004-2006
Member, Promotion and Tenure Committee, 2004-2005
Member, Faculty Achievement Award, Education Subcommittee, 2003-2004
Member, Search Committee, Head and Neck Surgical Oncology Chair, 2002-2003
Member, Research Laboratory Space Committee, 2001-2004
Member, Faculty Achievement Award, Education Subcommittee, 2001
Moderator, Academic Programs Faculty Development Program, "How to Enhance your Scientific Presentation Skills", 2000-2002
Member, Search Committee, Department of Gastrointestinal Medicine and Nutrition Chair, 2000-2001
Member, Research Council Subcommittee on Space Allocation, 1999-2001
Member, Faculty Leadership Forum, 1999-2001
Member, Executive Committee of the Science Faculty (ECSF), 1999
Member, Physicians Referral Service Grant Support Committee, 1998-2000
Member, Joint Committee for Academic Excellence, Promotion, and Tenure, 1998-1999
Member, Committee for Criteria for Faculty Excellence, 1997
Chairman, Microbiology and Recombinant DNA Subcommittee, Institutional Biosafety Committee, 1996-1997
Member, Biosafety Committee, 1995-1997
Member, Intellectual Property Committee, 1994-1996
Chairman, Institutional Research Support Committee, 1993-1994
Vice Chairman, Institutional Research Support Committee, 1992-1993
Member, Institutional Research Support Committee, 1991-1992

Honors and Awards

2013 Waun Ki Hong Award for Excellence in Team Science, The University of Texas MD Anderson Cancer Center
2012 Distiguished Teaching Professor, University of Texas
2012 Educator of the Month, The University of Texas MD Anderson Cancer Center
2012 Faculty Achievement Award in Education, The University of Texas MD Anderson Cancer Center
2012 Regent's Outstanding Teacher Award, The University of Texas Graduate School of Biomedical Sciences
2012 The William Randolph Hearst Foundations Faculty Achievement Award in Education, The University of Texas MD Anderson Cancer Center
2011 Gerald P. Bodey Award for Excellence in Education, The University of Texas MD Anderson Cancer Center
2010 Distinguished Research Faculty Mentor Award, The University of Texas MD Anderson Cancer Center
2007 Member, The University of Texas Academy of Health Science Education
2007 Recipient, Medallion for Education, The University of Texas Health Science Center at Houston
2006 Educator of the Month, The University of Texas MD Anderson Cancer Center
2002 President's Scholar Award for Teaching Nominee, The University of Texas Graduate School of Biomedical Sciences
2001-2003 Honors Convocation Recipient, The University of Texas Health Science Center at Houston
2000 Educator of the Month, The University of Texas MD Anderson Cancer Center
2000 Faculty Reappointment with Highest Commendation Reappointment, The University of Texas Graduate School of Biomedical Sciences
1991 John P. McGovern Outstanding Teaching Award, The University of Texas Graduate School of Biomedical Sciences
1975 Outstanding Teaching Award, University of Illinois
1970 Phi Eta Sigma, The University of Michigan
1970 William J. Branstrom Freshman Prize, The University of Michigan

Professional Memberships

American Association for Cancer Research Annual Meeting, Toronto, Canada
Member, Program Committee, 1985-present
American Association of Cancer Researchers, Houston, TX
Member, 1985-present
AstraZeneca Conference on Src Inhibition, London, England
Member, Advisory Board, 2003
Organ Systems Coordinating Center, Large Bowel Working Group
Member, 1986-1988
Panel for Integration for Study Sections NIH Committee
Member, 2006
Sprycel Pancreatic Cancer Advisory Board Meeting, San Francisco, CA
Member, 1/2011
Tissue Culture Association of America, Texas Branch, Houston, TX
Member, 1988-present
Tissue Culture Association of America, Texas Branch, Houston, TX
President, 1987-1988
Tissue Culture Association of America, Texas Branch, Houston, TX
Vice President, 1986-1987
Tissue Culture Association of America, Texas Branch, Houston, TX
Secretary, 1985-1986
UT Academy of Health Sciences Educators, Houston, TX
Member, 2009-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR-2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res 22(1):107-21, 1/2016. e-Pub 8/2015. PMCID: PMC4703437.
2. Hahn NM, Knudsen BS, Daneshmand S, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Liu Z, Breen T, Fleming MT, Lance R, Corless CL, Alva AS, Shen SS, Huang F, Gertych A, Gallick GE, Mallick J, Ryan C, Galsky MD, Lerner SP, Posadas EM, Sonpavde G. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urol Oncol 34(1):4.e11-7, 1/2016. e-Pub 9/9/2015. PMID: 26362343.
3. Lee YC, Lin SC, Yu G, Cheng CJ, Liu B, Liu HC, Hawke DH, Parikh NU, Varkaris A, Corn P, Logothetis C, Satcher RL, Yu-Lee LY, Gallick GE, Lin SH. Identification of bone-derived factors conferring de novo therapeutic resistance in metastatic prostate cancer. Cancer Res 75(22):4949-59, 11/15/2015. e-Pub 11/3/2015. PMCID: PMC4651787.
4. Gaur S, Wen Y, Song JH, Parikh NU, Mangala LS, Blessing AM, Ivan C, Wu SY, Varkaris A, Shi Y, Lopez-Berestein G, Frigo DE, Sood AK, Gallick GE. Chitosan Nanoparticle-Mediated Delivery of MiRNA-34a Decreases Prostate Tumor Growth in the Bone and its Expression Induces Non-Canonical Autophagy. Oncotarget 6(30):29161-77, 10/6/2015. e-Pub 7/22/2015. PMCID: PMC4745718.
5. Reddy SM, Kopetz S, Morris J, Parikh N, Qiao W, Overman MJ, Fogelman D, Shureiqi I, Jacobs C, Malik Z, Jimenez CA, Wolff RA, Abbruzzese JL, Gallick G, Eng C. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Invest New Drugs 33(4):977-84, 8/2015. e-Pub 6/12/2015. PMID: 26062928.
6. Jin JK, Tien PC, Cheng CJ, Song JH, Huang C, Lin SH, Gallick GE. Talin1 phosphorylation activates β1 integrins: a novel mechanism to promote prostate cancer bone metastasis. Oncogene 34(14):1811-21, 4/2/2015. e-Pub 5/5/2014. PMCID: PMC4221586.
7. Chatterji T, Varkaris AS, Parikh NU, Song JH, Cheng CJ, Schweppe RE, Alexander S, Davis JW, Troncoso P, Friedl P, Kuang J, Lin SH, Gallick GE. Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells. Oncotarget 6(12):10175-94, 4/30/2015. e-Pub 3/18/2015. PMCID: PMC4496348.
8. Sun S, Zhou X, Zhang W, Gallick GE, Kuang J. Unraveling the pivotal role of ALIX in MVB sorting and silencing of activated EGFR. Biochem J 466(3):475-87, 3/15/2015. e-Pub 12/16/2014. PMCID: PMC4495973.
9. Lee YC, Gajdosik MS, Josic D, Clifton JG, Logothetis C, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. Secretome analysis of an osteogenic prostate tumor identifies complex signaling networks mediating cross-talk of cancer and stromal cells within the tumor microenvironment. Mol Cell Proteomics 14(3):471-83, 3/2015. e-Pub 12/19/2014. PMCID: PMC4349970.
10. Yu G, Lee YC, Cheng CJ, Wu CF, Song JH, Gallick GE, Yu-Lee LY, Kuang J, Lin SH. RSK Promotes Prostate Cancer Progression in Bone through ING3, CKAP2 and PTK6-mediated Cell Survival. Mol Cancer Res 13(2):348-57, 2/2015. e-Pub 9/4/2014. PMCID: PMC4336832.
11. Sun S, Zhou X, Corvera J, Gallick GE, Lin SH, Kuang J. ALG-2 activates the MVB sorting function of ALIX through relieving its intramolecular interaction. Cell Discovery, 2015. e-Pub 2015.
12. Vishwamitra D, Curry CV, Alkan S, Song YH, Gallick GE, Kaseb AO, Shi P, Amin HM. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK(+) T-cell lymphoma. Mol Cancer 14(1):53, 2015. e-Pub 2/25/2015. PMCID: PMC4415347.
13. Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG. Src signaling pathways in prostate cancer. Cancer Metastasis Rev 33(2-3):595-606, 9/2014. e-Pub 2/2014. PMID: 24522479.
14. Wu CF, Liu S, Lee YC, Wang R, Sun S, Yin F, Bornmann WG, Yu-Lee LY, Gallick GE, Zhang W, Lin SH, Kuang J. RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B. Oncogene 33(18):2385-94, 5/2014. e-Pub 5/2013. PMCID: PMC4026278.
15. Henderson YC, Toro-Serra R, Chen Y, Ryu J, Frederick MJ, Zhou G, Gallick GE, Lai SY, Clayman GL. Src inhibitors in suppression of papillary thyroid carcinoma growth. Head Neck 36(3):375-84, 3/2014. e-Pub 6/1/2013. PMID: 23729178.
16. Satcher RL, Pan T, Cheng CJ, Lee YC, Lin SC, Yu G, Li X, Hoang AG, Tamboli P, Jonasch E, Gallick GE, Lin SH. Cadherin-11 in renal cell carcinoma bone metastasis. PLoS One 9(2):e89880, 2014. e-Pub 2/24/2014. PMCID: PMC3933681.
17. Kopetz S, Morris VK, Parikh N, Overman MJ, Jiang ZQ, Maru D, Elvin P, Gallick G. Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer. BMC Cancer 14:660, 2014. e-Pub 9/10/2014. PMCID: PMC4167273.
18. Liu T, Hu W, Dalton HJ, Choi HJ, Huang J, Kang Y, Pradeep S, Miyake T, Song JH, Wen Y, Lu C, Pecot CV, Bottsford-Miller J, Zand B, Jennings NB, Ivan C, Gallick GE, Baggerly KA, Hangauer DG, Coleman RL, Frumovitz M, Sood AK. Targeting Src and Tubulin in Mucinous Ovarian Carcinoma. Clin Cancer Res 19(23):6532-43, 12/2013. e-Pub 10/2013. PMCID: PMC3852199.
19. Bartley AN, Parikh N, Hsu CH, Roe DJ, Buckmeier JA, Corley L, Phipps RA, Gallick G, Lance P, Thompson PA, Hamilton SR. Colorectal adenoma stem-like cell populations: Associations with adenoma characteristics and metachronous colorectal neoplasia. Cancer Prev Res (Phila) 6(11):1162-70, 11/2013. e-Pub 9/2013. PMCID: PMC4079278.
20. Lee YC, Bilen MA, Yu G, Lin SC, Huang CF, Ortiz A, Cho H, Song JH, Satcher RL, Kuang J, Gallick GE, Yu-Lee LY, Huang W, Lin SH. Inhibition of Cell Adhesion by an Anti-cadherin 11 Antibody Thwarts Bone Metastasis. Mol Cancer Res 11(11):1401-11, 11/2013. e-Pub 8/2013. PMCID: PMC3834228.
21. Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE. Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer 133(7):1536-46, 10/2013. e-Pub 4/2013. PMCID: PMC3713179.
22. Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs 31(4):918-26, 8/2013. e-Pub 11/2012. PMID: 23179336.
23. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov 3(8):849-61, 8/2013. e-Pub 6/2013. PMCID: PMC3926428.
24. Dayyani F, Varkaris A, Araujo JC, Song JH, Chatterji T, Trudel GC, Logothetis CJ, Gallick GE. Increased Serum Insulin-like Growth Factor-1 Levels are Associated with Prolonged Response to Dasatinib-based Regimens in Metastatic Prostate Cancer. Prostate 73(9):In Press, 6/2013. e-Pub 1/2013. PMCID: PMC4013833.
25. Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, McIntyre BW, Logothetis CJ, Gallick GE, Lin SH. Targeting Constitutively Activated β1 Integrin inhibits Prostate Cancer Metastasis. Mol Cancer Res 11(4):405-17, 4/2013. e-Pub 1/2013. PMCID: PMC3631285.
26. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents. Clin Cancer Res 19(3):657-67, 2/2013. e-Pub 12/2012. PMCID: PMC3563727.
27. Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, Rodriguez-Aguayo C, Nagaraja AS, Gharpure KM, Wu Z, English RD, Soman KV, Shahzad MM, Shazhad MM, Zigler M, Deavers MT, Zien A, Soldatos TG, Jackson DB, Wiktorowicz JE, Torres-Lugo M, Young T, De Geest K, Gallick GE, Bar-Eli M, Lopez-Berestein G, Cole SW, Lopez GE, Lutgendorf SK, Sood AK. Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun 4:1403, 2013. PMCID: PMC3561638.
28. Kim KB, Prieto V, Joseph RW, Diwan AH, Gallick GE, Papadopoulos NE, Bedikian AY, Camacho LH, Hwu P, Ng CS, Wei W, Johnson MM, Wittemer SM, Vardeleon A, Reckeweg A, Colevas AD. A randomized phase II study of cilengitide (EMD 121974) in patients with metastatic melanoma. Melanoma Res 22(4):294-301, 8/2012. PMCID: PMC3880198.
29. Kim MP, Truty MJ, Choi W, Kang Y, Chopin-Lally X, Gallick GE, Wang H, McConkey DJ, Hwang R, Logsdon C, Abbruzzesse J, Fleming JB. Molecular Profiling of Direct Xenograft Tumors Established from Human Pancreatic Adenocarcinoma After Neoadjuvant Therapy. Ann Surg Oncol 19 Suppl 3:S395-403, 7/2012. e-Pub 6/2011. PMCID: PMC4112459.
30. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S, Logothetis CJ. Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1/2 study. Cancer 118(1):63-71, 1/2012. e-Pub 7/2011. PMCID: PMC3898168.
31. Gallick GE, Corn PG, Zurita AJ, Lin SH. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem 4(1):107-19, 1/2012. PMCID: PMC3285098.
32. Dayyani F, Parikh NU, Varkaris AS, Song JH, Moorthy S, Chatterji T, Maity SN, Wolfe AR, Carboni JM, Gottardis MM, Logothetis CJ, Gallick GE. Combined Inhibition of IGF-1R/IR and Src Family Kinases Enhances Antitumor Effects in Prostate Cancer by Decreasing Activated Survival Pathways. PLoS One 7(12):e51189, 2012. e-Pub 12/2012. PMCID: PMC3530555.
33. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs 20(12):1677-84, 12/2011. e-Pub 10/2011. PMCID: PMC4020016.
34. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer. J Natl Cancer Inst 103(22):1665-75, 11/2011. e-Pub 9/2011. PMCID: PMC4176261.
35. Lee YC, Cheng CJ, Bilen MA, Lu JF, Satcher RL, Yu-Lee LY, Gallick GE, Maity SN, Lin SH. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res 71(15):5194-203, 8/2011. e-Pub 6/2011. PMCID: PMC3148283.
36. Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK. Targeting Src in Mucinous Ovarian Carcinoma. Clin Cancer Res 17(16):5367-78, 8/2011. e-Pub 7/2011. PMCID: PMC4028171.
37. Jin JK, Dayyani F, Gallick GE. Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer 128(11):2545-61, 6/2011. e-Pub 3/2011. PMCID: PMC3082284.
38. Kim HS, Han HD, Armaiz-Pena GN, Stone RL, Nam EJ, Lee JW, Shahzad MM, Nick AM, Lee SJ, Roh JW, Nishimura M, Mangala LS, Bottsford-Miller J, Gallick GE, Lopez-Berestein G, Sood AK. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res 17(7):1713-1721, 4/2011. e-Pub 2/2011. PMCID: PMC3077122.
39. Liu JL, Mao Z, Gallick GE, Yung WK. AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor. Neuro Oncol 13(2):184-94, 2/2011. e-Pub 12/2010. PMCID: PMC3064623.
40. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 6(6):e20636, 2011. e-Pub 6/2011. PMCID: PMC3113804.
41. Zhou X, Si J, Corvera J, Gallick GE, Kuang J. Decoding the INTRINSIC mechanism that prohibits ALIX interaction with ESCRT and viral proteins. Biochem J 432(3):525-34, 12/2010. PMID: 20929444.
42. Connelly SF, Isley BA, Baker CH, Gallick GE, Summy JM. Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells. Mol Carcinog 49(12):1007-21, 12/2010. PMCID: PMC2991619.
43. Park SI, Kim SJ, McCauley LK, Gallick GE. Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol 51:Unit 14.15-27, 12/2010. PMCID: PMC3072580.
44. Wang R, Jung SY, Wu CF, Qin J, Kobayashi R, Gallick GE, Kuang J. Direct roles of the signaling kinase RSK2 in Cdc25C activation during Xenopus oocyte maturation. Proc Natl Acad Sci U S A 107(46):19885-90, 11/2010. e-Pub 11/2010. PMCID: PMC2993414.
45. Lee YC, Huang CF, Murshed M, Chu K, Araujo JC, Ye X, deCrombrugghe B, Yu-Lee LY, Gallick GE, Lin SH. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts. Oncogene 29(22):3196-207, 6/2010. e-Pub 3/2010. PMCID: PMC2921959.
46. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69(14):5820-8, 7/2009. e-Pub 7/2009. PMID: 19584296.
47. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9):3842-9, 5/2009. e-Pub 4/2009. PMCID: PMC2709758.
48. Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS, Ali S, Abbruzzese JL, Gallick GE, Sarkar FH. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69(6):2400-7, 3/2009. e-Pub 3/2009. PMCID: PMC2657919.
49. Sen B, Saigal B, Parikh N, Gallick G, Johnson FM. Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Res 69(5):1958-65, 3/2009. e-Pub 2/2009. PMCID: PMC2929826.
50. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 4(11):1670-80, 2009. e-Pub 10/2009. PMCID: PMC4203372.
51. Gorlov IP, Gallick GE, Gorlova OY, Amos C, Logothetis CJ. GWAS meets microarray: are the results of genome-wide association studies and gene-expression profiling consistent? Prostate cancer as an example. PLoS One 4(8):e6511, 2009. e-Pub 8/2009. PMCID: PMC2714961.
52. Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene 27(57):7192-200, 12/2008. e-Pub 9/2008. PMCID: PMC3199128.
53. Pan S, Wang R, Zhou X, Corvera J, Kloc M, Sifers R, Gallick GE, Lin SH, Kuang J. Extracellular Alix regulates integrin-mediated cell adhesions and extracellular matrix assembly. EMBO J 27(15):2077-90, 8/2008. e-Pub 7/2008. PMCID: PMC2516883.
54. Guan H, Zhou Z, Gallick GE, Jia SF, Morales J, Sood AK, Corey SJ, Kleinerman ES. Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Mol Cancer Ther 7(7):1807-16, 7/2008. PMCID: PMC2556989.
55. Mandal M, Myers JN, Lippman SM, Johnson FM, Williams MD, Rayala S, Ohshiro K, Rosenthal DI, Weber RS, Gallick GE, El-Naggar AK. Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features. Cancer 112(9):2088-100, 5/2008. PMID: 18327819.
56. Park SI, Zhang J, Phillips KA, Araujo JC, Najjar AM, Volgin AY, Gelovani JG, Kim SJ, Wang Z, Gallick GE. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res 68(9):3323-33 (*Highlight paper of the month), 5/2008. PMID: 18451159.
57. Dorfleutner A, Stehlik C, Zhang J, Gallick GE, Flynn DC. AFAP-110 is required for actin stress fiber formation and cell adhesion in MDA-MB-231 breast cancer cells. J Cell Physiol 213(3):740-9, 12/2007. PMID: 17520695.
58. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 14(12):3629-37, 12/2007. e-Pub 10/2007. PMID: 17909916.
59. Liu JL, Mao Z, LaFortune TA, Alonso MM, Gallick GE, Fueyo J, Yung WK. Cell cycle-dependent nuclear export of phosphatase and tensin homologue tumor suppressor is regulated by the phosphoinositide-3-kinase signaling cascade. Cancer Res 67(22):11054-63, 11/2007. PMID: 18006852.
60. Zhang J, Park SI, Artime MC, Summy JM, Shah AN, Bomser JA, Dorfleutner A, Flynn DC, Gallick GE. AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest 117(10):2962-73, 10/2007. PMCID: PMC1978423.
61. Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK. Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem 282(41):29919-26, 10/2007. e-Pub 8/2007. PMID: 17716980.
62. Estrella VC, Eder AM, Liu S, Pustilnik TB, Tabassam FH, Claret FX, Gallick GE, Mills GB, Wiener JR. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol 31(2):441-9, 8/2007. PMID: 17611702.
63. Wang R, He G, Nelman-Gonzalez M, Ashorn CL, Gallick GE, Stukenberg PT, Kirschner MW, Kuang J. Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition. Cell 128(6):1119-32, 3/2007. PMID: 17382881.
64. Herynk MH, Zhang J, Parikh NU, Gallick GE. Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells. J Exp Ther Oncol 6(3):205-17, 2007. PMID: 17552361.
65. Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 98(21):1558-70, 11/2006. PMID: 17077358.
66. Pan S, Wang R, Zhou X, He G, Koomen J, Kobayashi R, Sun L, Corvera J, Gallick GE, Kuang J. Involvement of the conserved adaptor protein Alix in actin cytoskeleton assembly. J Biol Chem 281(45):34640-50, 11/2006. PMID: 16966331.
67. Han LY, Landen CN, Trevino JG, Halder J, Lin YG, Kamat AA, Kim TJ, Merritt WM, Coleman RL, Gershenson DM, Shakespeare WC, Wang Y, Sundaramoorth R, Metcalf CA, Dalgarno DC, Sawyer TK, Gallick GE, Sood AK. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 66(17):8633-9, 9/2006. PMID: 16951177.
68. Yang L, Avila H, Wang H, Trevino J, Gallick GE, Kitadai Y, Sasaki T, Boyd DD. Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density--implications in tumor progression. Cancer Res 66(16):7957-67, 8/2006. PMID: 16912170.
69. Baker CH, Trevino JG, Summy JM, Zhang F, Caron A, Nesbit M, Gallick GE, Fidler IJ. Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice. Int J Oncol 29(1):125-38, 7/2006. PMID: 16773192.
70. Bauer TW, Somcio RJ, Fan F, Liu W, Johnson M, Lesslie DP, Evans DB, Gallick GE, Ellis LM. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther 5(7):1676-82, 7/2006. PMID: 16891453.
71. Lesslie DP, Summy JM, Parikh NU, Fan F, Trevino JG, Sawyer TK, Metcalf CA, Shakespeare WC, Hicklin DJ, Ellis LM, Gallick GE. Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases. Br J Cancer 94(11):1710-7, 6/2006. PMID: 16685275.
72. Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, Donato NJ, Abbruzzese JL, Baker CH, Gallick GE. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol 168(3):962-72, 3/2006. PMID: 16507911.
73. Trevino JG, Gray MJ, Nawrocki ST, Summy JM, Lesslie DP, Evans DB, Sawyer TK, Shakespeare WC, Watowich SS, Chiao PJ, McConkey DJ, Gallick GE. Src activation of Stat3 is an independent requirement from NF-kappaB activation for constitutive IL-8 expression in human pancreatic adenocarcinoma cells. Angiogenesis 9(2):101-10, 2006. PMID: 16871430.
74. Minard ME, Ellis LM, Gallick GE. Tiam1 regulates cell adhesion, migration and apoptosis in colon tumor cells. Clin Exp Metastasis 23(5-6):301-13, 2006. PMID: 17086355.
75. Summy JM, Trevino JG, Lesslie DP, Baker CH, Shakespeare WC, Wang Y, Sundaramoorthi R, Metcalf CA, Keats JA, Sawyer TK, Gallick GE. AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther 4(12):1900-11 (*Figure used for Journal Cover), 12/2005. PMID: 16373705.
76. Summy JM, Trevino JG, Baker CH, Gallick GE. c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK. Pancreas 31(3):263-74, 10/2005. PMID: 16163059.
77. Inoue S, Branch CD, Gallick GE, Chada S, Ramesh R. Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells. Mol Ther 12(4):707-15, 10/2005. PMID: 16054437.
78. Cabioglu N, Summy J, Miller C, Parikh NU, Sahin AA, Tuzlali S, Pumiglia K, Gallick GE, Price JE. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation. Cancer Res 65(15):6493-7, 8/2005. PMID: 16061624.
79. Trevino JG, Summy JM, Gray MJ, Nilsson MB, Lesslie DP, Baker CH, Gallick GE. Expression and activity of SRC regulate interleukin-8 expression in pancreatic adenocarcinoma cells: implications for angiogenesis. Cancer Res 65(16):7214-22, 8/2005. PMID: 16103072.
80. Liu JL, Sheng X, Hortobagyi ZK, Mao Z, Gallick GE, Yung WK. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol 25(14):6211-24, 7/2005. PMID: 15988030.
81. Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF, Stoeltzing O, Somcio R, Liu W, Evans DB, Klagsbrun M, Gallick GE, Ellis LM. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer 93(2):233-41, 7/2005. PMID: 15956974.
82. Bauer TW, Fan F, Liu W, Johnson M, Parikh NU, Parry GC, Callahan J, Mazar AP, Gallick GE, Ellis LM. Insulin like growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg 241(5):748-56; discussion 756-8, 5/2005. PMID: 15849510.
83. Gray MJ, Wey JS, Belcheva A, McCarty MF, Trevino JG, Evans DB, Ellis LM, Gallick GE. Neuropilin-1 suppresses tumorigenic properties in a human pancreatic adenocarcinoma cell line lacking neuropilin-1 coreceptors. Cancer Res 65(9):3664-70, 5/2005. PMID: 15867361.
84. Gray MJ, Zhang J, Ellis LM, Semenza GL, Evans DB, Watowich SS, Gallick GE. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 24(19):3110-20, 4/2005. PMID: 15735682.
85. Minard ME, Herynk MH, Collard JG, Gallick GE. The guanine nucleotide exchange factor Tiam1 increases colon carcinoma growth at metastatic sites in an orthotopic nude mouse model. Oncogene 24(15):2568-73, 4/2005. PMID: 15735692.
86. Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11(1):397-405, 1/2005. PMID: 15671571.
87. Minard ME, Kim LS, Price JE, Gallick GE. The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression. Breast Cancer Res Treat 84(1):21-32, 3/2004. PMID: 14999151.
88. Boyd DD, Wang H, Avila H, Parikh NU, Kessler H, Magdolen V, Gallick GE. Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness. Clin Cancer Res 10(4):1545-55, 2/2004. PMID: 14977859.
89. Kim SJ, Johnson M, Koterba K, Herynk MH, Uehara H, Gallick GE. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin Cancer Res 9(14):5161-70 (*Commentary in “The Biology Behind”), 11/2003. PMID: 14613995.
90. Liu W, Reinmuth N, Stoeltzing O, Parikh AA, Tellez C, Williams S, Jung YD, Fan F, Takeda A, Akagi M, Bar-Eli M, Gallick GE, Ellis LM. Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways. Cancer Res 63(13):3632-6, 7/2003. PMID: 12839952.
91. Herynk MH, Stoeltzing O, Reinmuth N, Parikh NU, Abounader R, Laterra J, Radinsky R, Ellis LM, Gallick GE. Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res 63(11):2990-6, 6/2003. PMID: 12782608.
92. Reinmuth N, Liu W, Ahmad SA, Fan F, Stoeltzing O, Parikh AA, Bucana CD, Gallick GE, Nickols MA, Westlin WF, Ellis LM. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res 63(9):2079-87, 5/2003. PMID: 12727823.
93. Boyd DD, Kim SJ, Wang H, Jones TR, Gallick GE. A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis. Am J Pathol 162(2):619-26, 2/2003. PMID: 12547719.
94. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 88(1):73-9, 1/2003. PMID: 12504632.
95. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R, Talpaz M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101(2):690-8, 1/2003. PMID: 12509383.
96. Herynk MH, Tsan R, Radinsky R, Gallick GE. Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated beta-catenin. Clin Exp Metastasis 20(4):291-300, 2003. PMID: 12856716.
97. Windham TC, Parikh NU, Siwak DR, Summy JM, McConkey DJ, Kraker AJ, Gallick GE. Src activation regulates anoikis in human colon tumor cell lines. Oncogene 21(51):7797-807, 11/2002. PMID: 12420216.
98. Reinmuth N, Fan F, Liu W, Parikh AA, Stoeltzing O, Jung YD, Bucana CD, Radinsky R, Gallick GE, Ellis LM. Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 82(10):1377-89, 10/2002. PMID: 12379772.
99. Haier J, Gallick GE, Nicolson GL. Src protein kinase pp60c-src influences adhesion stabilization of HT-29 colon carcinoma cells to extracellular matrix components under dynamic conditions of laminar flow. J Exp Ther Oncol 2(4):237-45, Jul-Aug, 7/2002. PMID: 12416028.
100. Davies MA, Kim SJ, Parikh NU, Dong Z, Bucana CD, Gallick GE||U. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 8(6):1904-14 (*Commentary in “The Biology Behind” ), 6/2002. PMID: 12060635.
101. Aligayer H, Boyd DD, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94(2):344-51, 1/2002. PMID: 11900220.
102. Solorzano CC, Jung YD, Bucana CD, McConkey DJ, Gallick GE, McMahon G, Ellis LM. In vivo intracellular signaling as a marker of antiangiogenic activity. Cancer Res 61(19):7048-51, 10/2001. PMID: 11585733.
103. Beresford SA, Davies MA, Gallick GE, Donato NJ. Differential effects of phosphatidylinositol-3/Akt-kinase inhibition on apoptotic sensitization to cytokines in LNCaP and PCc-3 prostate cancer cells. J Interferon Cytokine Res 21(5):313-22, 5/2001. PMID: 11429162.
104. Reinmuth N, Liu W, Jung YD, Ahmad SA, Shaheen RM, Fan F, Bucana CD, McMahon G, Gallick GE, Ellis LM. Induction of VEGF in perivascular cells defines a potential paracrine mechanism for endothelial cell survival. FASEB J 15(7):1239-41, 5/2001. PMID: 11344100.
105. Jung YD, Kim MS, Shin BA, Chay KO, Ahn BW, Liu W, Bucana CD, Gallick GE, Ellis LM. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer 84(6):844-50, 3/2001. PMID: 11259102.
106. Jung YD, Liu W, Reinmuth N, Ahmad SA, Fan F, Gallick GE, Ellis LM. Vascular endothelial growth factor is upregulated by interleukin-1 beta in human vascular smooth muscle cells via the P38 mitogen-activated protein kinase pathway. Angiogenesis 4(2):155-62, 2001. PMID: 11806247.
107. Jung YD, Nakano K, Liu W, Gallick GE, Ellis LM. Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. Cancer Res 59(19):4804-7, 10/1999. PMID: 10519388.
108. Ramdas L, Bunnin BA, Plunkett MJ, Sun G, Ellman J, Gallick GE, Budde RJ. Benzodiazepine compounds as inhibitors of the src protein tyrosine kinase: screening of a combinatorial library of 1,4-benzodiazepines. Arch Biochem Biophys 368(2):394-400, 8/1999. PMID: 10441393.
109. Wiener JR, Nakano K, Kruzelock RP, Bucana CD, Bast RC, Gallick GE. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res 5(8):2164-70, 8/1999. PMID: 10473101.
110. Allgayer H, Wang H, Gallick GE, Crabtree A, Mazar A, Jones T, Kraker AJ, Boyd DD. Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J Biol Chem 274(26):18428-37, 6/1999. PMID: 10373450.
111. Marchetti D, Parikh N, Sudol M, Gallick GE. Stimulation of the protein tyrosine kinase c-Yes but not c-Src by neurotrophins in human brain-metastatic melanoma cells. Oncogene 16(25):3253-60, 6/1998. PMID: 9681823.
112. Ellis LM, Staley CA, Liu W, Fleming RY, Parikh NU, Bucana CD, Gallick GE. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 273(2):1052-7, 1/1998. PMID: 9422768.
113. Fleming RY, Ellis LM, Parikh NU, Liu W, Staley CA, Gallick GE. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase. Surgery 122(2):501-7, 8/1997. PMID: 9288158.
114. Han NM, Fleming RY, Curley SA, Gallick GE. Overexpression of focal adhesion kinase (p125FAK) in human colorectal carcinoma liver metastases: independence from c-src or c-yes activation. Ann Surg Oncol 4(3):264-8, Apr-May, 4/1997. PMID: 9142389.
115. Staley CA, Parikh NU, Gallick GE. Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Differ 8(3):269-74, 3/1997. PMID: 9056668.
116. Han NM, Curley SA, Gallick GE. Differential activation of pp60(c-src) and pp62(c-yes) in human colorectal carcinoma liver metastases. Clin Cancer Res 2(8):1397-404, 8/1996. PMID: 9816313.
117. Ramdas L, Obeyesekere NU, McMurray JS, Gallick GE, Seifert WE, Budde RJ. A tyrphostin-derived inhibitor of protein tyrosine kinases: isolation and characterization. Arch Biochem Biophys 323(2):237-42, 11/1995. PMID: 7487083.
118. Novotny-Smith CL, Zorbas MA, Mcisaac AM, Irimura T, Boman BM, Yeoman LC, Gallick GE. Down-modulation of epidermal growth factor receptor accompanies TNF-induced differentiation of the DiFi human adenocarcinoma cell line toward a goblet-like phenotype. J Cell Physiol 157(2):253-62, 11/1993. PMID: 8227158.
119. Saya H, Lee PS, Nishi T, Izawa I, Nakajima M, Gallick GE, Levin VA. Bacterial expression of an active tyrosine kinase from a protein A/truncated c-src fusion protein. FEBS Lett 327(2):224-30, 7/1993. PMID: 7687570.
120. Termuhlen PM, Curley SA, Talamonti MS, Saboorian MH, Gallick GE. Site-specific differences in pp60c-src activity in human colorectal metastases. J Surg Res 54(4):293-8, 4/1993. PMID: 7687314.
121. Untawale S, Zorbas MA, Hodgson CP, Coffey RJ, Gallick GE, North SM, Wildrick DM, Olive M, Blick M, Yeoman LC. Transforming growth factor-alpha production and autoinduction in a colorectal carcinoma cell line (DiFi) with an amplified epidermal growth factor receptor gene. Cancer Res 53(7):1630-6, 4/1993. PMID: 8453634.
122. Talamonti MS, Roh MS, Curley SA, Gallick GE. Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest 91(1):53-60, 1/1993. PMID: 7678609.
123. Nicolson GL, Gallick GE, Spohn WH, Lembo TM, Tainsky MA. Transfection of activated c-H-rasEJ/pSV2neo or pSV2neo genes into rat mammary cells: rapid stimulation of clonal diversification of spontaneous metastatic and cell-surface properties. Oncogene 7(6):1127-35, 6/1992. PMID: 1594244.
124. Novotny-Smith CL, Gallick GE. Growth inhibition of human colorectal carcinoma cell lines by tumor necrosis factor-alpha correlates with reduced activity of pp60c-src. J Immunother 11(3):159-68, 4/1992. PMID: 1381217.
125. Putnam EA, Yen N, Gallick GE, Steck PA, Fang K, Akpakip B, Gazdar AF, Roth JA. Autocrine growth stimulation by transforming growth factor-alpha in human non-small cell lung cancer. Surg Oncol 1(1):49-60, 2/1992. PMID: 1341235.
126. Kim JS, Steck PA, Gallick GE, Lee JS, Blick M, Hong WK, Lotan R. Suppression by retinoic acid of epidermal growth factor receptor autophosphorylation and glycosylation in cultured human head and neck squamous carcinoma cells. J Natl Cancer Inst Monogr(13):101-10, 1992. PMID: 1389683.
127. Garcia R, Parikh NU, Saya H, Gallick GE. Effect of herbimycin A on growth and pp60c-src activity in human colon tumor cell lines. Oncogene 6(11):1983-9, 11/1991. PMID: 1719464.
128. Chiao PJ, Kannan P, Yim SO, Krizman DB, Wu TA, Gallick GE, Tainsky MA. Susceptibility to ras oncogene transformation is coregulated with signal transduction through growth factor receptors. Oncogene 6(5):713-20, 5/1991. PMID: 1646984.
129. Gross ME, Zorbas MA, Danels YJ, Garcia R, Gallick GE, Olive M, Brattain MG, Boman BM, Yeoman LC. Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res 51(5):1452-9, 3/1991. PMID: 1847663.
130. Nicolson GL, Gallick GE, Dulski KM, Spohn WH, Lembo TM, Tainsky MA. Lack of correlation between intercellular junctional communication, p21rasEJ expression, and spontaneous metastatic properties of rat mammary cells after transfection with c-H-rasEJ or neo genes. Oncogene 5(5):747-53, 5/1990. PMID: 2189108.
131. Donato NJ, Gallick GE, Steck PA, Rosenblum MG. Tumor necrosis factor modulates epidermal growth factor receptor phosphorylation and kinase activity in human tumor cells. Correlation with cytotoxicity. J Biol Chem 264(34):20474-81, 12/1989. PMID: 2555361.
132. Donato NJ, Ince C, Rosenblum MG, Gallick GE. Early events in the antiproliferative action of tumor necrosis factor are similar to the early events in epidermal growth factor growth stimulation. J Cell Biochem 41(3):139-57, 11/1989. PMID: 2482293.
133. Maxwell SA, Sacks PG, Gutterman JU, Gallick GE. Epidermal growth factor receptor protein-tyrosine kinase activity in human cell lines established from squamous carcinomas of the head and neck. Cancer Res 49(5):1130-7, 3/1989. PMID: 2783883.
134. Weber RS, Pathak S, Frankenthaler R, Gallick GE, Sacks PG. Effect of epidermal growth factor (EGF) on a newly established head and neck squamous carcinoma cell line. Otolaryngol Head Neck Surg 99(6):567-73, 12/1988. PMID: 3148118.
135. Lichtner RB, Gallick GE, Nicolson GL. Pyrimido-pyrimidine modulation of EGF growth-promoting activity and p21ras expression in rat mammary adenocarcinoma cells. J Cell Physiol 137(2):285-92, 11/1988. PMID: 3056958.
136. Tsuchiya H, Epstein J, Selvanayagam P, Dedman JR, Gallick GE, Alexanian R, Barlogie B. Correlated flow cytometric analysis of H-ras p21 and nuclear DNA in multiple myeloma. Blood 72(2):796-800, 8/1988. PMID: 3042048.
137. Sacks PG, Parnes SM, Gallick GE, Mansouri Z, Lichtner R, Satya-Prakash KL, Pathak S, Parsons DF. Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck. Cancer Res 48(10):2858-66, 5/1988. PMID: 2452013.
138. LaBiche RA, Yoshida M, Gallick GE, Irimura T, Robberson DL, Klostergaard J, Nicolson GL. Gene expression and tumor cell escape from host effector mechanisms in murine large cell lymphoma. J Cell Biochem 36(4):393-403, 4/1988. PMID: 3379107.
139. Lai CN, Gallick GE, Maxwell SA, Brinkley BR, Becker FF. Potassium inhibition of transforming protein P85gag-mos and reversal of the transformed phenotype in 6m2 cells. J Cell Physiol 134(3):445-52, 3/1988. PMID: 2965157.
140. Ro J, North SM, Gallick GE, Hortobagyi GN, Gutterman JU, Blick M. Amplified and overexpressed epidermal growth factor receptor gene in uncultured primary human breast carcinoma. Cancer Res 48(1):161-4, 1/1988. PMID: 3334990.
141. Biggart NW, Gallick GE, Murphy EC. Nickel-induced heritable alterations in retroviral transforming gene expression. J Virol 61(8):2378-88, 8/1987. PMID: 3037102.
142. Yoshida M, Gallick GE, Irimura T, Nicolson GL. Modification of cell surface glycoproteins, macrophage cytostasis, and blood-borne metastatic properties of the murine RAW117 large cell lymphoma by virus superinfection. Cancer Res 47(10):2558-62, 5/1987. PMID: 3567891.
143. Maxwell SA, Kurzrock R, Parsons SJ, Talpaz M, Gallick GE, Kloetzer WS, Arlinghaus RB, Kouttab NM, Keating MJ, Gutterman JU. Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Cancer Res 47(6):1731-9, 3/1987. PMID: 2434223.
144. Li W, Chi K, Gallick GE, Chan JC. Monoclonal antibody study of the subcellular localization and DNA-stimulating activity of murine sarcoma virus-activated transformation-associated proteins. Virology 156(1):91-100, 1/1987. PMID: 3027972.
145. Liang JC, Kurzrock R, Gutterman JU, Gallick GE. Trisomy 12 correlates with elevated expression of p21 ras in a human adenosquamous carcinoma of the lung. Cancer Genet Cytogenet 23(2):183-8, 10/1986. PMID: 3530433.
146. Kurzrock R, Gallick GE, Gutterman JU. Differential expression of p21ras gene products among histological subtypes of fresh primary human lung tumors. Cancer Res 46(3):1530-4, 3/1986. PMID: 3002619.
147. Steck PA, Gallick GE, Maxwell SA, Kloetzer WS, Arlinghaus RB, Moser RP, Gutterman JU, Yung WK. Expression of epidermal growth factor receptor and associated glycoprotein on cultured human brain tumor cells. J Cell Biochem 32(1):1-10, 1986. PMID: 3533968.
148. Gallick GE, Sacks PG, Maxwell SA, Steck PA, Gutterman JU. Head and neck squamous cell carcinoma cell lines as a model system for the study of oncogene expression during tumor progression and metastasis. Prog Clin Biol Res 212:97-111, 1986. PMID: 3012576.
149. Gallick GE, Sparrow JT, Singh B, Maxwell SA, Stanker LH, Arlinghaus RB. Recognition of mos-related proteins with an antiserum to a peptide of the v-mos gene product. J Gen Virol 66 (Pt 5):945-55, 5/1985. PMID: 2987403.
150. Gallick GE, Kurzrock R, Kloetzer WS, Arlinghaus RB, Gutterman JU. Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A 82(6):1795-9, 3/1985. PMID: 3885218.
151. Gallick GE, Hamelin R, Maxwell S, Duyka D, Arlinghaus RB. The gag-mos hybrid protein of ts110 Moloney murine sarcoma virus: variation of gene expression with temperature. Virology 139(2):366-74, 12/1984. PMID: 6097031.
152. Lai CN, Gallick GE, Arlinghaus RB, Becker FF. Temperature-dependent transmembrane potential changes in cells infected with a temperature-sensitive Moloney sarcoma virus. J Cell Physiol 121(1):139-42, 10/1984. PMID: 6480709.
153. Tumilowicz JJ, Gallick GE, East JL, Pathak S, Trentin JJ, Arlinghaus RB. Presence of retrovirus in the B95-8 Epstein-Barr virus-producing cell line from different sources. In Vitro 20(6):486-92, 6/1984. PMID: 6086497.
154. Gallick GE, Arlinghaus RB. Incorporation of lipids into variants of Moloney sarcoma virus which produce gag-mos fusion proteins. Virology 133(1):228-32, 2/1984. PMID: 6322433.
155. Stanker LH, Gallick GE, Horn JP, Arlinghaus RB. P85gag-mos encoded by ts110 Moloney murine sarcoma virus: rapid at the restrictive temperature. J Gen Virol 64 (Pt 10):2203-11, 10/1983. PMID: 6311952.
156. Stanker LH, Horn JP,Gallick GE, Kloetzer WS, Murphy EC, Blair DG, Arlinghaus RB. Gag-mos Polyproteins encoded by variants of the Moloney strain of mouse sarcoma virus. Virology 126(1):336-47, 4/1983. PMID: 6302990.
157. Wong PK, Soong MM, MacLeod R, Gallick GE, Yuen PH. A group of temperature-sensitive mutants of Moloney leukemia virus which is defective in cleavage of env precursor polypeptide in infected cells also induces hind-limb paralysis in newborn CFW/D mice. Virology 125(2):513-8, 3/1983. PMID: 6836918.
158. Stanker LH, Gallick GE, Kloetzer WS, Murphy EC, Arlinghaus RB. P85: a gag-mos polyprotein encoded by ts110 Moloney murine sarcoma virus. J Virol 45(3):1183-9, 3/1983. PMID: 6300456.
159. Rude R, Gallick GE, Wong PK. A fast replica plating technique for the isolation of post-integration mutants of the Moloney strain of murine leukemia virus. J Gen Virol 49(2):367-74, 8/1980. PMID: 7003062.
160. Wong PK, Gallick GE. Preliminary characterization of a temperature-sensitive mutant of Moloney murine leukemia virus that produces particles at the restrictive temperature. J Virol 25(1):187-92, 1/1978. PMID: 74422.

Invited Articles

1. Kim MP, Park SI, Kopetz S, Gallick GE. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res 335(1):249-259, 1/2009. e-Pub 9/2008. PMCID: PMC3907084.
2. Kopetz S, Shah AN, Gallick GE. Src continues aging: current and future clinical directions. Clin Cancer Res 13(24):7232-6, 12/2007. PMID: 18094400.
3. Johnson FM, Gallick GE. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer Agents Med Chem 7(6):651-9, 11/2007. PMID: 18045060.
4. Park SI, Shah AN, Zhang J, Gallick GE. Regulation of angiogenesis and vascular permeability by src family kinases: opportunities for therapeutic treatment of solid tumors. Expert Opin Ther Targets 11(9):1207-17, 9/2007. PMID: 17845146.
5. Park SI, Shah AN, Zhang J, Gallick GE. Regulation of angiogenesis and vascular permeability by src family kinases: opportunities for therapeutic treatment of solid tumours. Expt Opin Ther Targets 11:1207-17, 2007.
6. Trevino JG, Summy JM, Gallick GE. Src inhibitors as potential therapeutic agents for human cancers. Mini Rev Med Chem 6(6):681-7, 6/2006. PMID: 16787379.
7. Summy JM, Gallick GE. Treatment for advanced tumors: src reclaims center stage. Clin Cancer Res 12(5):1398-1401, 3/2006. PMID: 16533761.
8. Lesslie DP, Gallick GE. Src family kinases as regulators of angiogenesis: therapeutic implications. Clinical Cancer Therapy Reviews 1:45-50, 2005.
9. Gallick GE. SRC as a potential therapeutic target in solid tumor oncology. Clin Adv Hematol Oncol 2(7):435-7, 7/2004. PMID: 16163218.
10. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22(4):337-358, 12/2003. PMID: 12884910.
11. Gallick GE, Garcia RA, Staley SA, Moskal TL, Huang S, Chakrabarty S. Molecular alterations during colon tumorigenesis: an overview of growth regulatory pathways and potential therapeutic implications. Cancer Bull 46:296-302, 1994.
12. Jessup JM, Gallick GE. The biology of colorectal carcinoma. Curr Probl Cancer 16(5):263-328, Sep-Oct, 9/1992. PMID: 1337732.
13. Talamonti MS, Curley SA, Gallick GE, Teeter LD, Kuo MT. Development and progression of human colon cancer. Cancer Bull 44(4):321-326, 1992.
14. Gallick GE. Activation of pp60c-src kinase in human colorectal carcinoma. Cancer Bull 40(5):296-300, 1988.
15. Sacks PG, Gallick GE. New insights into growth and metastasis of squamous cell carcinoma of the upper aerodigestive tract. Cancer Bull 39(2):89-92, 1987.
16. Gallick GE, Tainsky MA. Relationship of oncogene expression to tumor progression and metastasis. Cancer Bull 39:153-156, 1987.
17. Steck PA, Gallick GE, Hwang TL, Yung WKA. Altered expression of cell surface glycoproteins as markers for brain tumors. Cancer Bull 38:10-14, 1986.


1. Kim MP,Gallick GE. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res 14(5):1284-5, 3/2008. PMID: 18316544.
2. Shah AN, Gallick GE. Src, chemoresistance and epithelial to mesenchymal transition: Are they related? Anticancer Drugs 18(4):371-5, 4/2007. PMID: 17351389.
3. Ellis LM, Gallick GE. Promiscuous transcription of vascular endothelial growth factor and survival of tumors. J Natl Cancer Inst 92(13):1030-1031, 7/2000. PMID: 10880538.
4. Gallick GE. Tyrosine kinase inhibitors for suppression of tumorigenic growth of Ras-transformed cells: PAK-ing in the signals. Cancer J 6(4):217-219, 7/2000. PMID: 11038141.

Book Chapters

1. Jon R. Weiner and Gallick GE. Nonreceptor Tyrosine Kinases and Their Roles in Cancer. In: Signaling Pathways in Cancer Pathogenesis and Therapy. Ed(s) David A. Frank. Springer Publishing Company: New York, New York, 39-53, 2012. ISBN: 978-1-4614-1215-1.
2. Johnson FM, Gallick GE. Family Kinase Inhibitors in Cancer Therapy Protein Kinase Inhibitors. In: New Research. Nova Science Publishers, Inc. Columbus, 2008.
3. Jessup JM, Liu B, Gallick GE. Molecular Biology of Colorectal Carcinoma: The Importance of the Wingless (Wg)/Wnt Signal Transduction Pathway. In: Molecular Basis of Human Cancer. Humana Press, 251-268, 2001.
4. Gallick GE, Talamonti MS, Nicolson GL. Activation and Expression of Proto-oncogenes in Human Endocrine Tumors. In: Endocrine Tumors. Blackwell Scientific Publications, 25-35, 1993.
5. Boman BM, Olive M, Untawale S, Blick M, North S, Gallick GE, Dolf G, Siciliano MJ, Roubein LD, Fritche H, Thomas G, Pathak S, Wildrick DM, Levin B. The DiFi Rectal Carcinoma Cell Line from a Familial Adenomatous Polyposis Patient: An in Vitro Model System to Study Genetic Changes in Colorectal Cancer. In: Hereditary Colorectal Cancer. Spring-Verlag, 541-548, 1990.
6. Gallick GE. Potential Roles of Activated Proto-oncogenes in Malignant Progression. In: Progressive Stages of Neoplastic Growth. Martinus Nijhoff Co., 1989.
7. Gallick GE, Sacks PG, Maxwell SA, Steck PA, Gutterman JU. Cell Lines from Human Squamous Tumors of the Head and Neck as Model Systems for the Study of Oncogene Expression During Tumor Progression and Metastasis. In: Cancer Metastasis: Experimental and Clinical Strategies. Alan R. Liss Inc., 97-111, 1986.
8. Gallick GE, Kurzrock R, Gutterman JU. Expression of p21ras Gene Products in Fresh Primary and Metastatic Human Tumor Tissue. In: Biochemistry and Molecular Genetics of Cancer Metastasis, 65-72, 1986.
9. Gallick GE, Brown DB, Murphy ECJr, Arlinghaus RB. Inhibition of Transformation in a Cell Line Infected with a Temperature-sensitive Mutant of Murine Sarcoma Virus (MuSV) by Cytoplasmic Microinjection of Purified IgG from an Antiserum Generated Against a Synthetic v-mos Peptide. In: Modern Approaches to Vaccines. Cold Spring Harbor Press, 407-413, 1984.

Grant & Contract Support

Title: MD Anderson Cancer Center Prostate Cancer SPORE - Project 2: Targeting Tumor Microenvironment-induced Therapy Resistance in Prostate Cancer Bone Metastasis
Funding Source: NIH/NCI
Role: Basic Co-Leader
Principal Investigator: Logothetis/Thompson
Duration: 4/1/2016 - 3/31/2021
Title: MD Anderson Cancer Center Prostate Cancer SPORE – Career Enhancement Program (CEP)
Funding Source: NIH/NCI
Role: Director
Principal Investigator: Logothetis/Thompson
Duration: 4/1/2016 - 3/31/2021
Title: Identifying Markers for Early Prediction of Prostate Cancer Bone Metastases in Prostate Cancer from Analyses of the Tumor-Associated Microenvironment
Funding Source: Prostate Cancer Foundation - Janssen Challenge Award
Role: Principal Investigator-MDACC
Principal Investigator: Logothetis/Gallick
Duration: 2/15/2016 - 2/15/2018
Title: Exosome-Based Strategies for Marker-Driven Treatment for Potentially Lethal Prostate Cancer
Funding Source: MDACC Sister Institution Network Fund
Role: Gallick/Navone MPIs
Duration: 1/1/2016 - 12/31/2017
Title: Mechanisms of de Novo and Acquired Resistance to Therapeutic Treatment of Bone-Metastatic Prostate Cancer
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 3/1/2015 - 2/28/2018
Title: Osteocrines in therapy resistance of prostate cancer bone metastasis: Evaluation of strategies to overcome therapy resistance from tumor-educated bone microenvironment
Funding Source: Prostate Cancer Foundation - Challenge Award
Role: Principal Investigator
Duration: 4/4/2014 - 4/3/2016
Title: Mechanisms of Resistance to Androgen Biosynthesis Inhibition in Castrate-Resistant Prostate Cancer Bone Metastases.
Funding Source: Prostate Cancer Foundation
Role: Co-Investigator
Principal Investigator: CHristopher J Logothetis
Duration: 6/1/2011 - 5/31/2013
Title: Reversal of Chemotherapy Resistance by the Src Substrate Inhibitor, KX01
Funding Source: Kinex Pharmaceuticals
Role: Principal Investigator
Duration: 4/1/2010 - 3/31/2011
Title: Individualized Microenvironment Targeted Therapy for Prostate Cancer Bone Metastases: Rapid Evaluation of Multiple Therapeutic Agents
Funding Source: Prostate Cancer Foundation, Creativity Award
Role: Co-Investigator
Principal Investigator: Christopher J Logothetis
Duration: 1/11/2010 - 12/31/2012
Title: SPORE in Prostate Cancer: Src as a Therapeutic Target in Prostate Cancer Bone Metastases
Funding Source: NIH/NCI
Role: Project Leader, Project 3
Principal Investigator: Christopher Logothetis
Duration: 9/2/2009 - 8/31/2014
Title: Preclinical Strategies for Selection of Patients with Metastatic Colon Cancer Susceptible to AZD0530 in Combination with Chemotherapy
Funding Source: AstraZeneca-Private Industry
Role: Principal Investigator
Duration: 9/1/2009 - 6/1/2013
Title: Role of Factors (Adipokines) Produced by Fat Cells in Prostate Cancer Bone Metastasis
Funding Source: Hamill Foundation Prostate Cancer Research Fund
Role: Principal Investigator
Duration: 6/1/2009 - 6/30/2012
Title: Training of Graduate Students and Clinical Fellows
Funding Source: Beimfohr Foundation
Role: Principal Investigator
Duration: 6/1/2009 - 6/30/2012
Title: Graduate Program in Cancer Metastasis Research: "From Bench to Bedside"
Funding Source: University of Texas System
Role: Principal Investigator
Duration: 3/1/2009 - 2/28/2014
Title: SHP-2 and c-Src in Pancreatic Cancer Cell Biology, Tumorigenesis, and Metastasis
Funding Source: Florida Department of Health
Role: Mentor
Principal Investigator: Justin Summy, PhD
Duration: 7/1/2008 - 6/30/2011
Title: SPORE in Pancreatic Cancer: Career Development Project - Roles of the Tyrosine Kinase c-Met Pancreatic Tumor Progression
Funding Source: DHHS/NIH
Role: Principal Investigator, Project 6
Principal Investigator: James Abbruzzese, MD
Duration: 9/30/2003 - 8/31/2011
Title: Regulation of u-PAR Expression in Colon Cancer
Funding Source: NCI
Role: Collaborator
Duration: 7/2003 - 6/2008
Title: Src Activation as a Mechanism of Tarceva Resistance
Funding Source: OSI Pharmaceuticals
Role: Principal Investigator

Last updated: 7/8/2016